NCT00282763终止2 期
Proprietary Information - Exploratory (Non-confirmatory) Trial
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 12
- 主要终点
- proprietary information - exploratory (non-confirmatory) trial
研究概览
简要总结
The purpose of this Study is to test the Safety and Effectiveness of MK0686 in relieving neuropathic (chronic) pain as experienced by patients with Postherpetic Neuralgia (Also Know as PHN or Post Shingles Pain).
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of postherpetic neuralgia with pain having lasted at least 6 months
- •Able to complete study questionnaires, patient diary, and comply with daily study medication
- •Patient is not satisfied with current treatment for pain control
排除标准
- •Pregnant or nursing female
- •History of evidence of a condition that in the opinion of the investigator, may interfere with the study results (e.g., diabetic neuropathy of fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease)
结局指标
主要结局
proprietary information - exploratory (non-confirmatory) trial
次要结局
- proprietary information - exploratory (non-confirmatory) trial
研究者
相似试验
终止
2 期
Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)Neuralgia, PostherpeticNCT00245544Merck Sharp & Dohme LLC20
已完成
2 期
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)ObesityNCT00109148Merck Sharp & Dohme LLC500
已完成
2 期
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)Diabetic Neuropathy, PainfulNCT01564459Merck Sharp & Dohme LLC170
已完成
2 期
A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)OsteoarthritisNCT00296569Merck Sharp & Dohme LLC150
已完成
2 期
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's DiseaseCrohn's DiseaseNCT00101946GlaxoSmithKline17